Catalyst Wire Dossier Catalyst Wire Dossier

naporafenib

naporafenib · Erasca, Inc.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for naporafenib, covering 2026-02-27 to 2026-02-27. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) [Phase 3]

See pricing